Skip to main content

Nivolumab and Relatlimab-rmbw

(nih-VOL-yoo-mab … reh-LAT-lih-mab)

This page contains brief information about nivolumab and relatlimab-rmbw and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Opdualag
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Nivolumab and relatlimab-rmbw is approved to treat:

Nivolumab and relatlimab-rmbw is a combination form of nivolumab and relatlimab. This form may work better than either drug alone. For more information about nivolumab that may apply to this combination drug, see the Drug Information Summary for Nivolumab.

Nivolumab and relatlimab-rmbw is also being studied in the treatment of other types of cancer.

More About Nivolumab and Relatlimab-rmbw

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3

Targeted Cancer Therapies

Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Nivolumab And Relatlimab-rmbw - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: